Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Jul;108(7):1023-30.
doi: 10.1016/j.rmed.2014.04.011. Epub 2014 Apr 29.

Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis

Luca Richeldi  1 , Vincent Cottin  2 , Kevin R Flaherty  3 , Martin Kolb  4 , Yoshikazu Inoue  5 , Ganesh Raghu  6 , Hiroyuki Taniguchi  7 , David M Hansell  8 , Andrew G Nicholson  8 , Florence Le Maulf  9 , Susanne Stowasser  10 , Harold R Collard  11
Affiliations
Free article
Randomized Controlled Trial

Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis

Luca Richeldi et al. Respir Med. 2014 Jul.
Free article

Abstract

Background: Nintedanib is in clinical development as a treatment for idiopathic pulmonary fibrosis (IPF). Data from the Phase II TOMORROW study suggested that nintedanib 150 mg twice daily had clinical benefits with an acceptable safety profile.

Methods: The INPULSIS™ trials are replicate Phase III, randomized, double-blind, studies comparing the efficacy and safety of nintedanib 150 mg twice daily with placebo in patients with IPF. Eligible patients were aged ≥40 years with a diagnosis of IPF within 5 years before randomization who had undergone a chest high-resolution computed tomography (HRCT) scan within 1-year before screening, and who had a forced vital capacity (FVC) of ≥50% predicted and a diffusing capacity for carbon monoxide of 30-79% predicted. Participants were randomized 3:2 to receive nintedanib or placebo for 52 weeks. The primary endpoint is the annual rate of decline in FVC. The key secondary endpoints are change from baseline in the total score on the St. George's Respiratory Questionnaire (a measure of health-related quality of life) over 52 weeks and time to first acute exacerbation.

Results: Enrolment of 1066 patients in 24 countries was completed in September 2012. Results will be reported in the first half of 2014.

Conclusion: The INPULSIS™ trials will determine the efficacy of nintedanib in patients with IPF, including its impact on disease progression as defined by decline in FVC, acute exacerbations and health-related quality of life. In addition, they will characterise the adverse event profile of nintedanib in this patient population.

Trial registration: Registered at ClinicalTrials.gov (identifiers: NCT01335464 and NCT01335477).

Keywords: Clinical trial; Drug therapy; Phase III; Protein kinase inhibitor; Protein tyrosine kinases.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms

Associated data

LinkOut - more resources